Airport screening in the U.S. detected the new variant in travelers arriving in California, Washington state, Virginia and ...

Sibling rivalry met viral internet absurdity on the latest episode of the New Heights podcast, where Jason and Travis Kelce found themselves at the center of an unexpected fan trib ...

An Onalaska man is accused of setting off fireworks in his neighbor’s bathroom in early June. According to criminal ...

Hundreds of Chippewa Valley tattoo lovers got a new sense of appreciation for the art form during the 2nd Sawdust City Tattoo Invitational. Old North Tattoo hosts a ...

While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past three years have been challenging for Pfizer (NYSE: PFE). Although Pfizer ...

COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. Fourteen months after an old tweet ...

Kristen Stewart flaunts her 'MINE' thigh tattoo at the 2025 Cannes Film Festival. Kristen attends the festival to represent her directorial debut 'The Chronology Of Water,' a stirring drama based ...

Pfizer's Oncology Transformation: Why This Beaten-Down Pharma Giant Is Poised For A Strong Comeback. Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure, he said ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...